Hepatocyte-like cells derived from human amniotic epithelial, bone marrow, and adipose stromal cells display enhanced functionality when cultured on decellularized liver substrate

Coronado, Ramon E.; Somaraki-Cormier, Maria; Ong, Joo L.; Halff, Glenn A.

doi:10.1016/j.scr.2019.101471

Cited by 17 publications

(13 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This characteristic initially gave hope to regenerative medicine. Previous studies have shown that MSCs derived from different tissues, such as bone marrow (BM-MSCs) (33), adipose tissue (AT-MSCs) (34), menstrual blood (MenSCs) (35), and amniotic fluid (AF-MSCs) (34), can differentiate into HLCs in vitro. Clinical and laboratory trials suggested that MSCs could significantly improve liver cell regeneration in different kinds of liver diseases.…”

Section: Role Of Msc In Tissue Repair and Regenerationmentioning

confidence: 99%

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

et al. 2021

View full text Add to dashboard Cite

Mesenchymal stem cell (MSC) transplantation is a novel treatment for liver diseases due to the roles of MSCs in regeneration, fibrosis inhibition and immune regulation. However, the mechanisms are still not completely understood. Despite the significant efficacy of MSC therapy in animal models and preliminary clinical trials, issues remain. The efficacy and safety of MSC-based therapy in the treatment of liver diseases remains a challenging issue that requires more investigation. This article reviews recent studies on the mechanisms of MSCs in liver diseases and the associated challenges and suggests potential future applications.

show abstract

Section: Role Of Msc In Tissue Repair and Regenerationmentioning

confidence: 99%

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Following grafting 2 × 10 6 of such AEC-HLCs in CCl 4 treated NOD-SCID mice, human cells were detected in the recipient liver (although the RI was not quantified) and liver injury was attenuated [104]. However, it remains to be addressed whether naïve AECs or in vitro differentiated AEC-HLCs are superior as an alternative cell source for alleviating liver failure and/or repopulating the host liver [114].…”

Section: Amniotic Epithelial Cellsmentioning

confidence: 99%

Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?

Tricot

Boeck

Verfaillie

2020

Cells

View full text Add to dashboard Cite

Acute and chronic liver failure is a highly prevalent medical condition with high morbidity and mortality. Currently, the therapy is orthotopic liver transplantation. However, in some instances, chiefly in the setting of metabolic diseases, transplantation of individual cells, specifically functional hepatocytes, can be an acceptable alternative. The gold standard for this therapy is the use of primary human hepatocytes, isolated from livers that are not suitable for whole organ transplantations. Unfortunately, primary human hepatocytes are scarcely available, which has led to the evaluation of alternative sources of functional hepatocytes. In this review, we will compare the ability of most of these candidate alternative cell sources to engraft and repopulate the liver of preclinical animal models with the repopulation ability found with primary human hepatocytes. We will discuss the current shortcomings of the different cell types, and some of the next steps that we believe need to be taken to create alternative hepatocyte progeny capable of regenerating the failing liver.

show abstract

“…65 Furthermore, researchers have found that hepatocytelike cells derived from human amniotic epithelial, bone marrow, and adipose stromal cells display enhanced functionality when cultured on a decellularized liver substrate. 66 To overcome the limitations due to the shortage of donor organs, Xiang et al 67 utilized the spleen as the source of a decellularized scaf fold for liver regeneration. The decellularized spleen scaffold could support the location and survival of BMSCs within the 3D matrix.…”

Section: Decellularized Matrixmentioning

confidence: 99%

Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source

Chen

Xiao

2020

Clin Mol Hepatol

View full text Add to dashboard Cite

End-stage liver disease is one of the leading causes of death around the world. Since insufficient sources of transplantable liver and possible immune rejection severely hinder the wide application of conventional liver transplantation therapy, artificial three-dimensional (3D) liver culture and assembly from stem cells have become a new hope for patients with end-stage liver diseases, such as cirrhosis and liver cancer. However, the induced differentiation of single-layer or 3D-structured hepatocytes from stem cells cannot physiologically support essential liver functions due to the lack of formation of blood vessels, immune regulation, storage of vitamins, and other vital hepatic activities. Thus, there is emerging evidence showing that 3D organogenesis of artificial vascularized liver tissue from combined hepatic cell types derived from differentiated stem cells is practical for the treatment of end-stage liver diseases. The optimization of novel biomaterials, such as decellularized matrices and natural macromolecules, also strongly supports the organogenesis of 3D tissue with the desired complex structure. This review summarizes new research updates on novel differentiation protocols of stem cell-derived major hepatic cell types and the application of new supportive biomaterials. Future biological and clinical challenges of this concept are also discussed.

show abstract

Hepatocyte-like cells derived from human amniotic epithelial, bone marrow, and adipose stromal cells display enhanced functionality when cultured on decellularized liver substrate

Cited by 17 publications

References 49 publications

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?

Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source

Contact Info

Product

Resources

About